Non-Small Cell Lung Cancer (NSCLC) - Metastatic

Recurrent or Metastatic (IIB, IV)

1st line

Squamous

Non-squamous

12.29.2020

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for Enrollment

In Development

Enrollment on Hold

IRB# 18084
S1609 (DART)

IRB# 19992 MATCH:
Molecular Analysis for Therapy Choice (MATCH)

IRB# 21325: RGX-104

CROSS-DISEASE TRIALS:

IRB# 21821 CodeBreak 101:
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (piKN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

IRB# 19330 LEAP-007:
A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

IRB# 21886 KEAPSAKE:
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Non-squamous NSCLC

IRB# 21821 CodeBreak 101:
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (piKN Sotorasib) plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-squamous NSCLC

IRB# 21770 EAS191:
A Phase II Study of SELPERCATINIB (LOXO-292) in Patients with RET Fusion Positive Stage IV or Recurrent Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP SUB-STUDY)

IRB# 21589 $1900C:
A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)

IRB# 21821 CodeBreak 101:
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (piKN Sotorasib) in Combination With AMG 404 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

IRB# 21821 CodeBreak 101:
A Phase 2 Randomized, Multicenter, Double-Blind Study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)